Clinical Trial

Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program

Study acronym: aSAH-Omics
Recruiting
View on ClinicalTrials.gov →
Summary
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening cerebrovascular emergency with high mortality and disability rates. Despite advances in neuroimaging and interventional techniques, outcomes remain poor for many patients due to complex post-rupture complications such as delayed cerebral ischemia (DCI), pneumonia, and other systemic injuries. These secondary events critically affect neurological recovery, yet their molecular mechanisms are not fully understood. This multicenter study aims to investigate the biological basis of post-rupture complications and prognosis in patients with aSAH through integrated multi-omics and clinical data analysis. Biospecimens including blood, cerebrospinal fluid, urine, and other relevant tissues will be collected for genomic, transcriptomic, proteomic, metabolomic, and imaging-omic profiling. By linking molecular data with clinical and imaging indicators, the study seeks to identify key pathways and biomarkers associated with secondary injury and outcome heterogeneity.
Trial Details
NCT Number NCT07270419
Lead Sponsor Xiaolin Chen, MD
Collaborators: Peking Union Medical College
Conditions Aneurysmal Subarachnoid Hemorrhage
Enrollment 2,000 participants
Start Date 2023-11-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-08